Rhythm Pharma Reports Strong Additional Phase 3 Data for Setmelanotide in Hypothalamic Obesity Ahead of PDUFA Date

summarizeSummary

Rhythm Pharmaceuticals announced additional positive Phase 3 data for setmelanotide in acquired hypothalamic obesity, reinforcing its efficacy and strengthening the case for upcoming regulatory approvals in the US, Europe, and Japan.

check_boxKey Events · Product Development and Regulatory · RYTM

• Positive Phase 3 TRANSCEND Data

  Rhythm Pharmaceuticals reported additional 52-week data from its Phase 3 TRANSCEND trial for setmelanotide in acquired hypothalamic obesity, showing a -18.8% placebo-adjusted difference in BMI reduction (N=142) and significant hunger score reduction.

• Strengthens Regulatory Outlook

  This new data reinforces the efficacy profile of setmelanotide, bolstering the supplemental New Drug Application (sNDA) currently under FDA review with a PDUFA goal date of March 20, 2026.

• Global Market Expansion

  The company is also pursuing marketing authorization in Europe, with an anticipated CHMP opinion in Q2 2026, and plans to seek approval in Japan, targeting a significant global patient population for acquired hypothalamic obesity.

auto_awesomeAnalysis · RYTM · Life Sciences

The additional positive Phase 3 data for setmelanotide in acquired hypothalamic obesity significantly strengthens Rhythm Pharmaceuticals' regulatory position ahead of the March 20, 2026 PDUFA goal date. The robust efficacy demonstrated in BMI and hunger score reduction, including new Japanese and supplemental patient cohorts, de-risks the potential FDA approval. This positive development, coupled with ongoing EMA review and plans for Japanese submission, expands the potential market opportunity for setmelanotide in a rare disease with high unmet need, reinforcing the company's growth trajectory.